Octaplex
Sponsors
Octapharma
Conditions
Acute Major BleedingBleeding Cardiac Surgery PatientsSignificant Bleeding Risk
Phase 3
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
CompletedNCT02740335
Start: 2017-06-08End: 2022-02-23Updated: 2023-03-08
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
TerminatedNCT04867837
Start: 2021-09-01End: 2026-01-13Updated: 2026-06-25
Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
CompletedNCT05523297
Start: 2022-11-30End: 2024-06-27Updated: 2025-08-15